Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study

被引：0
|
作者：
Xinguang Wang
Zhaoqing Fan
Xing Wang
Yingjian He
Yiqiang Liu
Xiang Wang
Bailin Zhang
Zefei Jiang
Tao Wang
Zhigang Yu
Fei Wang
Yinhua Liu
Yanping Li
Jianguo Zhang
Bin Luo
Hongchuan Jiang
Tianfeng Wang
Yuntao Xie
Jinfeng Li
Tao Ouyang
机构：
[1] Peking University Cancer Hospital & Institute,Breast Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Peking University Cancer Hospital & Institute,Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Breast Surgical Oncology
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Oncology
[5] The Fifth Medical Center of PLA General Hospital,Department of Breast Surgery, Cheeloo College of Medicine, The Second Hospital
[6] Shandong University,Breast Disease Center
[7] Peking University First Hospital,Department of Breast Surgery, Beijing Shijitan Hospital
[8] Capital Medical University,Department of Breast Surgery
[9] The Second Hospital of Harbin Medical University,Department of General Surgery, Clinical School of Medicine, Tsinghua Changgung Hospital
[10] Tsinghua University,Department of Breast Surgery, Beijing Chao Yang Hospital
[11] Capital Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 195卷
关键词：
Neoadjuvant endocrine therapy; Breast cancer; Pathological response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 50 条
  • [1] Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study
    Wang, Xinguang
    Fan, Zhaoqing
    Wang, Xing
    He, Yingjian
    Liu, Yiqiang
    Wang, Xiang
    Zhang, Bailin
    Jiang, Zefei
    Wang, Tao
    Yu, Zhigang
    Wang, Fei
    Liu, Yinhua
    Li, Yanping
    Zhang, Jianguo
    Luo, Bin
    Jiang, Hongchuan
    Wang, Tianfeng
    Xie, Yuntao
    Li, Jinfeng
    Ouyang, Tao
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (03) : 301 - 310
  • [2] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2024, 123
  • [3] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [4] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    [J]. FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [5] HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie
    Gonyo, MaryBeth
    Kong, Amanda
    Peck, Amy R.
    Sun, Yunguang
    Bergom, Carmen
    Banarjee, Anjishnu
    Chitambar, Christopher
    Rui, Hallgeir
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [6] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    [J]. Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [7] The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis
    Zhang, Linhui
    Song, Guohong
    Shao, Bin
    Xu, Ling
    Xiao, Yu
    Wang, Mopei
    Sumou, Ingrid Karmane
    Zhang, Yan
    Liang, Xu
    Jiang, Hanfang
    Li, Huiping
    [J]. ANTI-CANCER DRUGS, 2022, 33 (01) : E635 - E643
  • [8] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Yayoi Adachi
    Isao Oze
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Haruru Kotani
    Ayumi Kataoka
    Kayoko Sugino
    Nanae Horisawa
    Yuri Ozaki
    Yuka Endo
    Kazuki Nozawa
    Daiki Takatsuka
    Hiroji Iwata
    [J]. Breast Cancer, 2021, 28 : 1087 - 1095
  • [9] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    [J]. SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [10] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Adachi, Yayoi
    Oze, Isao
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kotani, Haruru
    Kataoka, Ayumi
    Sugino, Kayoko
    Horisawa, Nanae
    Ozaki, Yuri
    Endo, Yuka
    Nozawa, Kazuki
    Takatsuka, Daiki
    Iwata, Hiroji
    [J]. BREAST CANCER, 2021, 28 (05) : 1087 - 1095
12345